B O O K - American College of Rheumatology

ACR Poster Session B
1123. Safety of a Novel Modified-Release (MR) Prednisone
Formulation: Results of the “Circadian Administration of
Prednisone in Rheumatoid Arthritis” (CAPRA) Studies. Frank
Buttgereit 1 , Jacek Szechinski 5 , Gisela Döring 6 , Stephan Witte 2 ,
Christine Knauer 3 , Amy Grahn 4 , Kenneth G. Saag 8 and Rieke
Alten 7 , 1 Charite University Med-Berlin, Berlin, Germany,
2
Horizon Pharma GmbH, Mannheim, Germany, 3 Horizon
Pharma GmbH, Mannheim, Germany, 4 Horizon Pharma, Inc.,
Northbrook, IL, 5 Med. Uni. Department of Rheumatology,
Wroclaw, Poland, 6 Merck KGaA, 7 Schlosspark-Klinik, UnivMed,
Berlin, Germany, 8 University of Alabama-Birmingham,
Birmingham, AL.
1124. Safety, Pharmacokinetics and Pharmacodynamics of ALD518
(BMS-945429), a High-Affinity Monoclonal Antibody Directed
Against Interleukin-6 (IL-6) Administered by Subcutaneous
Injection: A Phase I Trial. Sepehr Shakib 2 , Barbara Francis 1 and
Jeffrey Smith 1 , 1 Alder Biopharmaceuticals Inc., Bothell, WA,
2
Royal Adelaide Hospital, Adelaide, Australia.
1125. Selective Activation of Naturally Occurring Regulatory T Cells
(Tregs) by the Monoclonal Antibody (mAb) BT-061. Markers
of Clinical Activity and Early Phase II Results in Patients
with Rheumatoid Arthritis (RA). Anatoliy Rudnev 1 , Sukanya
Ragavan 6 , Christina Trollmo 6 , Vivianne Malmstroem 6 , Christian
Becker 5 , Helmut Jonuleit 5 , Vibeke Strand 7 , Silke Aigner 1 , Niklas
Czeloth 1 , Benjamin Daelken 1 , Andre Engling 1 , Helga Koch 1 ,
Gabriele Niemann 1 , Frank Osterroth 1 , Christoph Uherek 1 ,
Andrea Wartenberg-Demand 1 , Olga Ershova 4 , Tatiana Sotnikova 2
and Alexander Orlov-Morozov 3 , 1 Biotest AG, Dreieich, Germany,
2
Botkin Clinical Hospital, Moscow, Russian Federation, 3 City
Clinical Hospital Nr. 23 n.a. Medsantrud, Moscow, Russian
Federation, 4 Clinical Hospital for Emergency Medical Care,
Yaroslavl, Russian Federation, 5 Johannes-Gutenberg University,
Mainz, Germany, 6 Karolinska Institute, Stockholm, Sweden,
7
Stanford University, Portola Valley, CA.
1126. Serum Cytokine Profile Predicts Response to Rituximab
Therapy in Rheumatoid Arthritis. Edward M. Vital 4 , Richard J.
Cuthbert 4 , Shouvik Dass 1 , Rekha Parmar 4 , Andrew C. Rawstron 3 ,
Frederique C. Ponchel 1 and Paul Emery 2 , 1 Leeds, West Yorkshire,
United Kingdom, 2 Chapel Allerton Hospital, Leeds, United
Kingdom, 3 Leeds Teaching Hospitals NHS Trust, Leeds, West
Yorkshire, United Kingdom, 4 University of Leeds, Leeds, West
Yorkshire, United Kingdom.
1127. Serum Markers Associated with Structural Damage in
Methotrexate Naïve Rheumatoid Arthritis Patients Treated
with MTX in Combination with Placebo or Golimumab, a
Human Anti-TNFa Monoclonal Antibody. Carrie Wagner 2 ,
Dion Chen 1 , Hongtao Fan 1 , Sudha Visvanathan 5 , Elizabeth C.
Hsia 3 , Paul Emery 4 , Roy M. Fleischmann 6 , Michael Mack 1 and
Mahboob U. Rahman 3 , 1 Centocor Research and Development,
Inc., 2 Centocor Research and Development, Inc., Malvern,
PA, 3 Centocor Research and Development, Inc./Univ. of
Pennsylvania School of Medicine, Malvern, PA, 4 Chapel
Allerton Hospital, Leeds, United Kingdom, 5 Hoffmann La Roche,
6
University of Texas SW Medical Center, Dallas, TX.
1128. Targeting Potassium Channels for the Treatment of
Rheumatoid Arthritis. Xueyou Hu 2 , Teresina Laragione 4 , Liang
Sun 2 , Shyny Koshy 2 , Karlie R. Jones 2 , Frank T. Horrigan 2 , Percio
S. Gulko 3 and Christine Beeton 1 , 1 Baylor College of Medicine,
Houston, TX, 2 Baylor College of Medicine, 3 Feinstein Institute
for Medical Research, Manhasset, NY, 4 Feinstein Institute for
Medical Research.
1129. Tasocitinib (CP-690,550), an Orally Available Selective Janus
Kinase Inhibitor, Exhibits Sustained Safety and Efficacy in the
Treatment of Rheumatoid Arthritis over 24 Months. Carol A.
Connell, Richard Riese, Susan Wood, John Bradley and Samuel
H. Zwillich, Pfizer Inc.
1130. The Bacterial Effector Protein YopM Reduces Bone Destruction
in Rheumatoid Arthritis (RA). Jessica Bertrand 1 , Christian
Rüter 3 , Julia Scharnert 3 , Alexander Schmidt 3 and Thomas Pap 2 ,
1
Institute for Experimental Musculoskeletal Medicine, Münster,
Germany, 2 Institute for Experimental Musculoskeletal Medicine,
3
Institute for Infectiology ZMBE.
1131. The Effects of Manzamine A on Rheumatoid Arthritis
Synoviocyte Cytokine Secretion. Kyle Chong 1 , Karolina
Klosowska 1 and James M. Woods 2 , 1 Midwestern University,
Downers Grove, IL, 2 Midwestern University.
1132. The Hawthorne Effect, Sponsored Trials, and the
Overestimation of Treatment Effectiveness. Frederick Wolfe 1
and Kaleb D. Michaud 2 , 1 National Data Bank for Rheumatic
Diseases, Wichita, KS, 2 Univ of Nebraska Med Ctr, Omaha, NE.
1133. The Relationship of Serum Cytokine Levels with Disease
Activity Parameters and Ultrasonographic Findings in RA
Patients before and after Treatment with TNF Antagonists.
Nevsun Inanc 2 , Atilla Bulur 2 , Meryem Can 2 , Onder Ergonul 1 ,
Pamir Atagunduz 2 , Sule Yavuz 2 and Haner Direskeneli 2 ,
1
Marmara University Medical School, Department of Infectious
Diseases, 2 Marmara University Medical School, Division of
Rheumatology.
1134. Therapeutic Potential of Human Umbilical Cord Mesenchymal
Stem Cells in the Treatment of Rheumatoid Arthritis. Yanying
Liu, Rong Mu, Shiyao Wang and Zhanguo Li, Peking University
People’s Hospital.
1135. TRA-8 (CS-1008), a Novel Anti-Arthritic Biologic Agent That
Targets Macrophages with Low Toxicity. Jun Li 1 , Hui-Chen Hsu 2 ,
PingAr Yang 2 , Qi Wu 2 and John D. Mountz 1 , 1 Division of Clinical
Immunology and Rheumatology, Department of Medicine,
University of Alabama at Birmingham, Birmingham, AL, 2 Division
of Clinical Immunology and Rheumatology, Department of
Medicine, University of Alabama at Birmingham, Birmingham,
AL.
1136. Treat-To-Target for the Management of Rheumatoid Arthritis:
A Validation Using Patient Reported Outcomes Data from
Two Phase III Clinical Trials of Golimumab. Ed C. Keystone 6 ,
Roy M. Fleischmann 4 , Chenglong Han 3 , Paul Emery 2 , Mark C.
Genovese 5 , Timothy Gathany 3 , Elizabeth C. Hsia 1 and Mahboob
U. Rahman 1 , 1 Centocor Research and Development, Inc./Univ. of
Pennsylvania School of Medicine, Malvern, PA, 2 Chapel Allerton
Hospital, Leeds, United Kingdom, 3 Johnson and Johnson
Pharmaceutical Services, LLC, 4 Rheumatology Associates, Dallas,
TX, 5 Stanford University, Sunnyvale, CA, 6 University of Toronto,
Toronto, ON, Canada.
1137. WITHDRAWN
1138. Validation of an Algorithm Using Genome-Wide SNP Analysis
for Prediction of Responders, Non-Responders, and Adverse
Events of Tocilizumab-Treated RA Patients Using Two
Population Samples from Multiple Medical Cohorts. Tsukasa
Matsubara 5 , Satoru Koyano 10 , Keiko Funahashi 10 , Takafumi
Hagiwara 6 , Takako Miura 5 , Kosuke Okuda 5 , Akira Sagawa 11 ,
Takeo Sakurai 2 , Hiroaki Matsuno 7 , Tomomaro Izumihara 3 , Eisuke
Shono 12 , Kou Katayama 4 , Toyomitsu Tsuchida 13 , Mitsuhiro
Iwahashi 1 , Tomomi Tsuru 9 and Motohiro Oribe 8 , 1 Higashi-
218
2010 Program Book